The single-cell analysis market in North America is predicted to grow from USD 0.96 billion in 2023 to USD 2.01 billion by 2028, growing at a CAGR of 15.89% from 2023 to 2028.
Wide application of single-cell analysis in cancer research, increased R&D in the pharmaceutical and biotechnology industry, and growing stem cell research activities are a few factors primarily accelerating the growth of the single-cell analysis market. Being regarded as a powerful tool by researchers, single-cell analysis is used in identifying disease-specific biomarkers, monitoring disease onset, diagnosing various diseases, and recording the progression of patient response to treatment. In addition, single-cell analysis helps analyze complex tissues at the single-cell level, which is the most crucial step in identifying differential gene expression, leading to real-time monitoring of the progression of tumor development.
The growing number of people who have cancer from North American countries favors the single-cell analysis market in North America. The application of single-cell analysis in cancer genomics has seen a spike in the last few years, mainly due to the rising prevalence of this disease, making single-cell analysis an essential part of this investigation. Furthermore, efficient cell sorting, sequencing, microfluidics, and single-cell amplification have resulted due to technological developments, making it applicable to other areas such as proteomics, genomics, transcriptomics, and metabolomics. The significant advantage is that diagnosis, monitoring, and treatment of diseases become more effective through analyzing every individual cell. This has not only helped in the determination of DNA content but also helped in the enumeration of helper T cells for central malignancies treatment. Moreover, technological advancements in single-cell analysis, the increase in genome mapping programs leading to more adoption of next-generation sequencing, and the constant need for consumables necessary for the assay are foreseen to drive the single-cell analysis market in the Asia-Pacific region.
However, the high costs are one of the key factors hampering the growth of the single-cell analysis market in North America. Especially when maintaining high-quality standards, expensive items for adhering to regulatory standards is concerned, making it difficult for academic and research laboratories to afford, making the overall process quite expensive.
This research report on the North American single-cell analysis market has been segmented and sub-segmented into the following categories:
North America was the most dominant region in the global market in 2022. Furthermore, the domination of this region in the global market is expected to continue throughout the forecast period. The adoption of single-cell analyzers is growing significantly in the North American region owing to the well-established healthcare system as a result of numerous government funding programs, increased consumer awareness of the costs associated with personal healthcare, aging population leading to an increasing prevalence of targeted diseases has resulted in increasing acceptance of single-cell technology in the region of North America.
The U.S. accounted for a significant share of the North American market in 2022. During the forecast period, the United States is foreseen to contribute significantly to the dominance of the single-cell analysis market in North America. Due to the widespread usage of advanced analytical tools and methodologies for diagnosing, researching, and treating various diseases, the adoption of single-cell analysis has increased. In addition, favorable reimbursement policies, the presence of key market participants in the United States, growing spending on R&D, and federal funding are fuelling the growth of the single-cell analysis market in the United States. Furthermore, well-developed healthcare infrastructure, increased research in cancer treatments due to the high rise in cancer cases, paving the way for technological advances in single-cell analysis products with the help from R&D in the pharmaceutical and biotechnology sectors, leading to increased stem cell research for efficient diagnosis and treatment of cancers, along with increased expenditure on personalized medicine by the population.
KEY MARKET PLAYERS:
A few of the notable companies operating in the North American single-cell analysis market profiled in the report are Merck KGaA, Becton, Dickinson and Company, Promega Corporation, Danaher Corporation, General ElectricCompany, Thermo Fisher Scientific, Miltenyi Biotec, Illumina, Bio-Rad Laboratories, Fluidigm Corporation, NanoString Technologies, Agilent Technologies, Abcam Plc, NuGEN Technologies Inc., LumaCyte, PluriSelect Life Science UG & Co. KG, Sysmex Partec, Bio-Techne Corporation, Promega Corporation, 10x Genomics, WaferGen Bio-systems, Bruker, and Fluxion Bioscience.
Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2000
Call us on: +1 888 702 9696 (U.S Toll Free)
Write to us: email@example.com